Integrative omics analyses broaden treatment targets in human cancer.
Genome Medicine
Sengupta, Sohini S; Sun, Sam Q SQ; Huang, Kuan-Lin KL; Oh, Clara C; Bailey, Matthew H MH; Varghese, Rajees R; Wyczalkowski, Matthew A MA; Ning, Jie J; Tripathi, Piyush P; McMichael, Joshua F JF; Johnson, Kimberly J KJ; Kandoth, Cyriac C; Welch, John J; Ma, Cynthia C; Wendl, Michael C MC; Payne, Samuel H SH; Fenyö, David D; Townsend, Reid R RR; Dipersio, John F JF; Chen, Feng F; Ding, Li L
BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Pediatric Blood & Cancer
Chisholm, Julia C JC; Suvada, Jozef J; Dunkel, Ira J IJ; Casanova, Michela M; Zhang, Weijiang W; Ritchie, Natasha N; Choi, YounJeong Y; Park, Jane J; Das Thakur, Meghna M; Simko, Stephen S; Wan Rachel Tam, Nga N; Ferrari, Andrea A
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes.
Nature Genetics
Leiserson, Mark D M MD; Vandin, Fabio F; Wu, Hsin-Ta HT; Dobson, Jason R JR; Eldridge, Jonathan V JV; Thomas, Jacob L JL; Papoutsaki, Alexandra A; Kim, Younhun Y; Niu, Beifang B; McLellan, Michael M; Lawrence, Michael S MS; Gonzalez-Perez, Abel A; Tamborero, David D; Cheng, Yuwei Y; Ryslik, Gregory A GA; Lopez-Bigas, Nuria N; Getz, Gad G; Ding, Li L; Raphael, Benjamin J BJ